Skip to content
DataLookout
Menu

RECTIFY-1NCT07735624

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 48 words Show 4 more changesShow less
    • Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
    • Start date changed from estimate of Sep 2026 to Aug 10, 2026
    • Secondary endpoints: details revised at 4 of 6 entries
    • Site details revised at 1 of 3 sites
  2. Notable Recruitment opened
    • Site details revised at 3 of 3 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Complete response (cCR plus nCR with pCR at resection) within 6 months from initiation of therapy or nCR with pathologic complete response (pCR) with TES
Timeframe: From baseline to 6 months from initiation of therapy

Secondary (6)

Incidence of treatment-emergent adverse events
Incidence of surgical complications
Organ preservation rate
3-year locoregional recurrence rate
Disease-free survival
Show 1 moreShow less
Overall survival

Arms and interventions

Botensilimab + BalstilimabExperimental

Participants receive: * Botensilimab: one IV infusion on Cycle 1 Day 1, over about 30 minutes * Balstilimab: IV infusion every 2 weeks on Day 1 of each treatment cycle, over about 30 minutes, for up to 6 months The protocol specifies: * Botensilimab dose: 75 mg IV once * Balstilimab dose: 240 mg IV every 2 weeks for up to 6 months

Drugs: Botensilimab, Balstilimab

Sites

3 sites in 1 country